Poor prognostic role of the pretreatment platelet counts in colorectal cancer

et al. 2020

BMC Pulm Med

Background: The prognostic value of elevated pretreatment platelet counts remains controversial in lung cancer patients. We performed the present meta-analysis to determine its precise role in these patients. Methods: We employed a multiple search strategy in the PubMed, EMBASE and Cochrane Library databases to identify eligible studies. Disease-free survival (DFS)/progression-free survival (PFS)/time to progression (TTP) and overall survival (OS) were used as outcomes with hazard ratios (HRs) and 95% confidence intervals (CIs). Heterogeneity among the studies and publication bias were also evaluated. Results: A total of 40 studies including 16,696 lung cancer patients were eligible for the analysis. Overall, the pooled analysis showed that compared with normal platelet counts, elevated pretreatment platelet counts were associated with poorer OS (HR = 1.54, 95% CI: 1.37-1.72, P < 0.001) and poorer DFS/PFS/TTP (HR = 1.62, 95% CI: 1.33-1.98, P < 0.001) in patients with lung cancer. In subgroup analyses, elevated pretreatment platelet counts were also associated with poorer OS and DFS/PFS/TTP in most subgroups. There was no evidence of publication bias. Conclusions: This meta-analysis revealed that elevated pretreatment platelet counts were an independent predictor of OS and DFS/PFS/TTP in lung cancer patients. Large-scale prospective studies and a validation study are warranted.

Section: Discussionmentioning

confidence: 99%

Prognostic value of pretreatment platelet counts in lung cancer: a systematic review and meta-analysis

Yuan

et al. 2020

BMC Pulm Med

“…In the 1960s, Richard B observed that the platelet count is elevated in patients with cancers compared to those with nonmalignant diseases 5 . Accumulating evidence suggests that elevated platelet counts are associated with various cancers, such as colorectal cancer, lung cancer, and endometrial carcinoma 12,66,67 . Platelets sustain proliferative signalling, resist cell death, and induce tumour angiogenesis 68 .…”

Section: Discussionmentioning

confidence: 99%

Prognostic value of pretreatment platelet counts in lung cancer: a systematic review and meta-analysis

Yuan¹,

Liang³

et al. 2020

Preprint

Background : The prognostic value of elevated pretreatment platelet counts remains controversial in lung cancer patients. We performed the present meta-analysis to determine its precise role in these patients. Methods: We employed a multiple search strategy in the PubMed, EMBASE and Cochrane Library databases to identify eligible studies. Disease-free survival (DFS)/progression-free survival (PFS)/time to progression (TTP) and overall survival (OS) were used as outcomes with hazard ratios (HRs) and 95% confidence intervals (CIs). Heterogeneity among the studies and publication bias were also evaluated. Results : A total of 40 studies including 16696 lung cancer patients were eligible for the analysis. Overall, the pooled analysis showed that compared with normal platelet counts, elevated pretreatment platelet counts were associated with poorer OS (HR= 1.54, 95% CI: 1.37-1.72, P<0.001) and poorer DFS/PFS/TTP (HR=1.62, 95% CI: 1.33-1.98, P<0.001) in patients with lung cancer. In subgroup analyses, elevated pretreatment platelet counts were also associated with poorer OS and DFS/PFS/TTP in most subgroups. There was no evidence of publication bias. Conclusions : This meta-analysis revealed that elevated pretreatment platelet counts were an independent predictor of OS and DFS/PFS/TTP in lung cancer patients. Large-scale prospective studies and a validation study are warranted.

“…Since the 1960s, RICHARD B had observed that platelet count elevated in patients with cancers compared to those with nonmalignant diseases 5 . Accumulating evidence suggesting that elevated platelet is associated with various cancers such as colorectal cancer, lung cancer, endometrial carcinoma and so on 12,66,67 .…”

Section: Discussionmentioning

confidence: 99%

Prognostic value of pretreatment platelet count in lung cancer: a systematic review and meta-analysis

Yuan¹,

Liang³

et al. 2020

Preprint

Background : The prognostic value of pretreatment elevated platelet count remains controversial in lung cancer patients. We performed the present meta-analysis to determine the precise role of it in these patients. Methods: We performed a multiple search strategy in PubMed database, EMBASE and Cochrane Library to identify eligible studies. Disease-free survival (DFS) /Progress-free survival (PFS)/Time to progress (TTP) and Overall survival (OS) were used as outcomes with hazard ratio (HR) and its 95% confidence intervals (CIs). Heterogeneity among studies and publication bias were also evaluated. Results : A total of 40 studies including 16696 lung cancer patients were eligible in the analysis. Overall, the pooled analysis showed that pretreatment elevated platelet count was associated with poorer OS (HR= 1.54, 95%CI:1.37-1.72, P<0.001) and poorer DFS/PFS/TTP (HR=1.62, 95%CI: 1.33-1.98, P<0.001) in patients with lung cancer compared with normal platelet count. In subgroup analyses, pretreatment elevated platelet count was also associated with poorer OS and DFS/PFS/TTP in most subgroups. There was no evidence of publication bias. Conclusions : This meta-analysis revealed that pretreatment elevated platelet count was an independent predictor of OS and DFS/PFS/TTP in lung cancer patients. Large scale prospective studies and a validation study are warranted.